HOME   
   NEWS   
   BUSINESS   
   CRICKET   
   SPORTS   
   MOVIES   
   NET GUIDE   
   SHOPPING   
   BLOGS  
   ASTROLOGY  
   MATCHMAKER  


Search:



The Web

Rediff








Business
Portfolio Tracker
Business News
Specials
Columns
Market Report
Mutual Funds
Interviews
Tutorials
Message Board
Stock Talk



Home > Business > Business Headline > Report

IT-biotech link-up mooted

Anusha Subramanian in Mumbai | February 18, 2003 12:59 IST

There is a need for an immediate convergence between information technology and biotechnology to tap the $2.84 billion Indian pharmaceutical market, pharmaceutical industry experts said.

Speaking at a chief investment officers' roundtable on healthcare held last week by the National Association of Software and Services Companies, industry experts said that the pharmaceutical industry is undergoing a paradigm shift, which demanded a change in the business models.

The CIOs noted that the reverse engineering concept could do to the pharmaceutical sector what body shopping did to IT.

The near unanimous verdict on the areas of convergence came up at the conference were reducing the time for clinical trials to increase the return on investment, extensive automation for sales force, mining the vast information repository, sprucing up the research and development work and to ensure compliance with regulatory issues.

Ajit Dangi, director general of the Organisation of Pharmaceutical Producers of India, felt that today the pharmaceutical industry is undergoing a paradigm shift where there is a need to change the business model from changing the base from chemistry to biology.

"As a result, information technology  can be increasingly harnessed in the fields of bio-statistics, bio-informatics, proteomics and genomics," he said.

This can enable Indian companies to tap the $40 billion US R&D market. Consequently, they can increase R&D spending three times in the next 10 years.

One more silver lining for the industry is with 53 of the top 100 drugs coming off patent by 2005, the market is ripe for utilisation by Indian companies.


Powered by



Article Tools

Email this Article

Printer-Friendly Format

Letter to the Editor



Related Stories


Biotech bug bites Ranbaxy

Sudler, Rediffusion in pact



People Who Read This Also Read


Foreigners seek Indian IT services

Exult setting up centre in India

India to build new refinery by '06







HOME   
   NEWS   
   BUSINESS   
   CRICKET   
   SPORTS   
   MOVIES   
   NET GUIDE   
   SHOPPING   
   BLOGS  
   ASTROLOGY  
   MATCHMAKER  
© 2003 rediff.com India Limited. All Rights Reserved.